G. Ya. Sylenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
G. Ya. Sylenko has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Kateryna Tarianyk
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
3 shared publications - A. M. Kryvchun
Poltava State Medical University of the Ministry of Health of Ukraine, Poltava, Ukraine
2 shared publications - I. I. Delva
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
2 shared publications - Kateryna V. Hryn
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
2 shared publications - Mykhailo Yu. Delva
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
2 shared publications - Tetiana Purdenko
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
2 shared publications
Latest Publications
- 30 April 2026
- Published by V. N. Karazin Kharkiv National University in Psychiatry, Neurology and Medical Psychology
- p. 355
Secondary hyperkalemic paralysis (clinical case)
Background. Secondary hyperkalemic paralysis (SHP) is a specific and rare manifestation of hyperkalemia characterized by acute (subacute) symmetrical flaccid paresis. If SHP is not recognized promptly, the further progression of hyperkalemia can lead to the development of fatal cardiac arrhythmias and respiratory failure. Purpose – presentation of a clinical case of SHP. Materials and Methods. A clinical case of SHP in the form of transient lower paraplegia in a patient with newly diagnosed multiple myeloma complicated by acute nephropathy is reported. Results. A 53-year-old male patient was admitted to the emergency department complaining of a lack of movement in his lower limbs. About 6 hours ago, he suddenly experienced weakness in both lower limbs, and about 2 hours ago, movement in both legs disappeared. There is no active movement in both lower limbs, but muscle strength in the upper limbs is normal. Muscle tone in the upper limbs is normal, but significantly reduced in the lower limbs. Deep reflexes in the upper limbs are reduced and symmetrical, but absent in the lower limbs. No pyramidal symptoms, sensory and coordination disorders, meningeal symptoms were detected. ECG: sinus bradycardia 51/min, high-pointed T waves, widened QRS complexes. Biochemical blood analysis: creatinine – 3295.3 μmol/L (70–115), urea – 76.4 mmol/L (<8.3), potassium – 9.4 mmol/L (3.3–5.5), calcium – 3.07 mmol/L (2.15–2.55). On the same day, during acute hemodialysis, the patient began to move his lower limbs. The next day, strength in the legs was fully restored, and serum potassium was 6.05 mmol/L. Conclusions. In cases of acute (subacute) tetraparesis or lower paraparesis, SHP should be ruled out, especially in patients with kidney disease.
- 30 April 2026
- Published by V. N. Karazin Kharkiv National University in Psychiatry, Neurology and Medical Psychology
- p. 355
Secondary hyperkalemic paralysis (clinical case)
Background. Secondary hyperkalemic paralysis (SHP) is a specific and rare manifestation of hyperkalemia characterized by acute (subacute) symmetrical flaccid paresis. If SHP is not recognized promptly, the further progression of hyperkalemia can lead to the development of fatal cardiac arrhythmias and respiratory failure. Purpose – presentation of a clinical case of SHP. Materials and Methods. A clinical case of SHP in the form of transient lower paraplegia in a patient with newly diagnosed multiple myeloma complicated by acute nephropathy is reported. Results. A 53-year-old male patient was admitted to the emergency department complaining of a lack of movement in his lower limbs. About 6 hours ago, he suddenly experienced weakness in both lower limbs, and about 2 hours ago, movement in both legs disappeared. There is no active movement in both lower limbs, but muscle strength in the upper limbs is normal. Muscle tone in the upper limbs is normal, but significantly reduced in the lower limbs. Deep reflexes in the upper limbs are reduced and symmetrical, but absent in the lower limbs. No pyramidal symptoms, sensory and coordination disorders, meningeal symptoms were detected. ECG: sinus bradycardia 51/min, high-pointed T waves, widened QRS complexes. Biochemical blood analysis: creatinine – 3295.3 μmol/L (70–115), urea – 76.4 mmol/L (<8.3), potassium – 9.4 mmol/L (3.3–5.5), calcium – 3.07 mmol/L (2.15–2.55). On the same day, during acute hemodialysis, the patient began to move his lower limbs. The next day, strength in the legs was fully restored, and serum potassium was 6.05 mmol/L. Conclusions. In cases of acute (subacute) tetraparesis or lower paraparesis, SHP should be ruled out, especially in patients with kidney disease.
- Open Access
- 25 November 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (7) , 491-498
Chronic inflammatory axonal polyneuropathy (clinical case report, discussion)
The purpose was to demonstrate the significance of knowledge of diagnostic criteria for rare types of polyneuropathy among neurologists by describing a clinical case of chronic inflammatory axonal polyneuropathy. Female patient V., 51 years old, complained of unpleasant sensations in both feet and lower legs, weakness in the legs, and walking difficulties. She has been suffering for 4 months since she noticed burning sensations in her feet for no obvious reason. The patient has repeatedly sought medical help from family doctor, neurologists. She was diagnosed with idiopathic polyneuropathy of the lower extremities, for which repeatedly underwent outpatient and inpatient treatment. Despite this, discomfort in her feet increased, and she began to experience leg fatigue and walking difficulties. At the initial examination, peripheral lower distal moderate paraparesis, decreased pain and tactile sensitivity in the feet and the distal parts of the lower leg, impaired muscle-joint and vibration sensitivity in the toes were detected. Gait was paraparetic with ataxia. The following findings were revealed during additional examinations: high levels of cyanocobalamin in the blood (the patient was taking vitamin B12), primary axonal type of nerve fiber lesions by electroneuromyography, and elevated protein levels in the cerebrospinal fluid. Diagnosis was chronic inflammatory axonal polyneuropathy with moderate distal paraparesis of the lower extremities, sensory ataxia. The following treatment was prescribed: prednisolone 60 mg per day, omeprazole, and spironolactone. At the end of the second week of taking prednisolone, the patient noticed a decrease in unpleasant sensations in her legs and improved walking. After 2 months, the dysesthesia in her legs completely disappeared, muscle strength in the legs was restored, and walking was normalized. At the follow-up examination, full restoration of strength in the leg muscles, of muscle-joint sensation in the toes, and vibration sensitivity in the feet were noted. Neurologists need to be aware of and use diagnostic criteria for chronic inflammatory axonal polyneuropathy to ensure adequate treatment.
- 25 November 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL NEUROLOGICAL JOURNAL
- Vol. 21 (7) , 491-498
Open AccessChronic inflammatory axonal polyneuropathy (clinical case report, discussion)
The purpose was to demonstrate the significance of knowledge of diagnostic criteria for rare types of polyneuropathy among neurologists by describing a clinical case of chronic inflammatory axonal polyneuropathy. Female patient V., 51 years old, complained of unpleasant sensations in both feet and lower legs, weakness in the legs, and walking difficulties. She has been suffering for 4 months since she noticed burning sensations in her feet for no obvious reason. The patient has repeatedly sought medical help from family doctor, neurologists. She was diagnosed with idiopathic polyneuropathy of the lower extremities, for which repeatedly underwent outpatient and inpatient treatment. Despite this, discomfort in her feet increased, and she began to experience leg fatigue and walking difficulties. At the initial examination, peripheral lower distal moderate paraparesis, decreased pain and tactile sensitivity in the feet and the distal parts of the lower leg, impaired muscle-joint and vibration sensitivity in the toes were detected. Gait was paraparetic with ataxia. The following findings were revealed during additional examinations: high levels of cyanocobalamin in the blood (the patient was taking vitamin B12), primary axonal type of nerve fiber lesions by electroneuromyography, and elevated protein levels in the cerebrospinal fluid. Diagnosis was chronic inflammatory axonal polyneuropathy with moderate distal paraparesis of the lower extremities, sensory ataxia. The following treatment was prescribed: prednisolone 60 mg per day, omeprazole, and spironolactone. At the end of the second week of taking prednisolone, the patient noticed a decrease in unpleasant sensations in her legs and improved walking. After 2 months, the dysesthesia in her legs completely disappeared, muscle strength in the legs was restored, and walking was normalized. At the follow-up examination, full restoration of strength in the leg muscles, of muscle-joint sensation in the toes, and vibration sensitivity in the feet were noted. Neurologists need to be aware of and use diagnostic criteria for chronic inflammatory axonal polyneuropathy to ensure adequate treatment.
- 28 November 2022
- Published by V. N. Karazin Kharkiv National University in Actual problems of modern medicine
- No. 10,p. 30-38
Ghrelin as a biomarker of non-motor symptoms and sleep disorders at Parkinson's disease
Among the movement disorders characterized by Parkinson's disease, an equally important component is non-motor symptoms. To date, the neurophysiological basis of development and potential biomarkers of the disease remain insufficiently studied. The purpose of our study is to analyze the possibility of using the level of ghrelin in blood plasma as a biomarker of non-motor symptoms and sleep disturbances in Parkinson's disease depending on circadian rhythms. We examined 64 patients with Parkinson's disease registered at the Center for Parkinson's Disease and Other Neurodegenerative Diseases, Department of Nervous Diseases, Poltava State Medical University, and 30 patients without signs of neurodegenerative disease. The diagnosis was established according to the criteria of the World Brain Bank of Great Britain. Non-motor manifestations were studied according to the results of the non-motor symptom assessment scale, the severity of sleep disorders was assessed according to the sleep scale at Parkinson's disease. Results. In the course of the study, a decrease in the level of ghrelin in the blood plasma and the connection of the ghrelin content with sleep and digestive system disorders in patients with Parkinson's disease were established. patients, which is consistent with other studies. Ghrelin stimulates motility and emptying of the stomach, as well as motility of the small and large intestines. This indicates the probable role of ghrelin in the pathophysiology of diseases of the digestive system at Parkinson's disease. Conclusions. The level of plasma ghrelin in patients with Parkinson's disease and its diurnal fluctuations can be considered as a potential biomarker of non-motor symptoms and their fluctuations due to its links with sleep disorders and circadian rhythm.
- 28 November 2022
- Published by V. N. Karazin Kharkiv National University in Actual problems of modern medicine
- No. 10,p. 30-38
Ghrelin as a biomarker of non-motor symptoms and sleep disorders at Parkinson's disease
Among the movement disorders characterized by Parkinson's disease, an equally important component is non-motor symptoms. To date, the neurophysiological basis of development and potential biomarkers of the disease remain insufficiently studied. The purpose of our study is to analyze the possibility of using the level of ghrelin in blood plasma as a biomarker of non-motor symptoms and sleep disturbances in Parkinson's disease depending on circadian rhythms. We examined 64 patients with Parkinson's disease registered at the Center for Parkinson's Disease and Other Neurodegenerative Diseases, Department of Nervous Diseases, Poltava State Medical University, and 30 patients without signs of neurodegenerative disease. The diagnosis was established according to the criteria of the World Brain Bank of Great Britain. Non-motor manifestations were studied according to the results of the non-motor symptom assessment scale, the severity of sleep disorders was assessed according to the sleep scale at Parkinson's disease. Results. In the course of the study, a decrease in the level of ghrelin in the blood plasma and the connection of the ghrelin content with sleep and digestive system disorders in patients with Parkinson's disease were established. patients, which is consistent with other studies. Ghrelin stimulates motility and emptying of the stomach, as well as motility of the small and large intestines. This indicates the probable role of ghrelin in the pathophysiology of diseases of the digestive system at Parkinson's disease. Conclusions. The level of plasma ghrelin in patients with Parkinson's disease and its diurnal fluctuations can be considered as a potential biomarker of non-motor symptoms and their fluctuations due to its links with sleep disorders and circadian rhythm.